3
|
Arthur S, Mottok A, Cojocaru R, Jiang A, Grande B, Alcaide M, Rushton C, Ennishi D, Kumar Lat P, Davidson J, Bushell K, Audas T, Unrau P, Sen D, Gascoyne R, Marra M, Connors J, Morin G, Scott D, Steidl C, Morin R. FUNCTIONAL CHARACTERIZATION OF NFKBIZ
3′ UTR MUTATIONS IN DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.43_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S.E. Arthur
- Molecular Biology & Biochemistry; Simon Fraser University; Burnaby Canada
| | - A. Mottok
- Centre for Lymphoid Cancer; BC Cancer; Vancouver Canada
| | - R. Cojocaru
- Molecular Biology & Biochemistry; Simon Fraser University; Burnaby Canada
| | - A. Jiang
- Molecular Biology & Biochemistry; Simon Fraser University; Burnaby Canada
| | - B.M. Grande
- Molecular Biology & Biochemistry; Simon Fraser University; Burnaby Canada
| | - M. Alcaide
- Molecular Biology & Biochemistry; Simon Fraser University; Burnaby Canada
| | - C. Rushton
- Molecular Biology & Biochemistry; Simon Fraser University; Burnaby Canada
| | - D. Ennishi
- Centre for Lymphoid Cancer; BC Cancer; Vancouver Canada
| | - P. Kumar Lat
- Molecular Biology & Biochemistry; Simon Fraser University; Burnaby Canada
| | - J. Davidson
- Molecular Biology & Biochemistry; Simon Fraser University; Burnaby Canada
| | - K.R. Bushell
- Molecular Biology & Biochemistry; Simon Fraser University; Burnaby Canada
| | - T. Audas
- Molecular Biology & Biochemistry; Simon Fraser University; Burnaby Canada
| | - P. Unrau
- Molecular Biology & Biochemistry; Simon Fraser University; Burnaby Canada
| | - D. Sen
- Molecular Biology & Biochemistry; Simon Fraser University; Burnaby Canada
| | - R.D. Gascoyne
- Centre for Lymphoid Cancer; BC Cancer; Vancouver Canada
| | - M.A. Marra
- Genome Sciences Centre; BC Cancer; Vancouver Canada
| | - J.M. Connors
- Centre for Lymphoid Cancer; BC Cancer; Vancouver Canada
| | - G.B. Morin
- Genome Sciences Centre; BC Cancer; Vancouver Canada
| | - D.W. Scott
- Centre for Lymphoid Cancer; BC Cancer; Vancouver Canada
| | - C. Steidl
- Centre for Lymphoid Cancer; BC Cancer; Vancouver Canada
| | - R.D. Morin
- Molecular Biology & Biochemistry; Simon Fraser University; Burnaby Canada
| |
Collapse
|
4
|
Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, Ennishi D, Tamaru JI, Ishizawa K, Kashimura M, Kagami Y, Sunami K, Yamane H, Nishikori M, Kosugi H, Yujiri T, Hyo R, Katayama N, Kinoshita T, Nakamura S. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 2011; 22:1601-1607. [PMID: 21199885 DOI: 10.1093/annonc/mdq627] [Citation(s) in RCA: 86] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) shows poor prognosis and frequent central nervous system (CNS) relapses under anthracycline-containing chemotherapy. The aim of this study was to determine the prognosis and CNS relapse incidence of CD5+ DLBCL in the rituximab era. PATIENTS AND METHODS We analyzed 337 patients with CD5+ DLBCL who received chemotherapy with (R-chemotherapy group; n = 184) or without (chemotherapy group; n = 153) rituximab. RESULTS No significant difference was found in clinical background comparisons between the two groups. In the R-chemotherapy group, 60% of the patients were older than 65 years at diagnosis. Both the complete response rate and overall survival (OS) were significantly better in the R-chemotherapy group (P = 0.0003 and P = 0.002, respectively). Multivariate analysis confirmed that chemotherapy without rituximab was associated with unfavorable OS. However, the probability of CNS relapse did not differ between the two groups (P = 0.89). The CNS relapse was strongly associated with short OS (P < 0.0001). In the R-chemotherapy group, 83% of patients who experienced CNS relapse had parenchymal disease. CONCLUSIONS Our results indicate that rituximab improves the OS of patients with CD5+ DLBCL but does not decrease the CNS relapse rate. More effective treatments with CNS prophylaxis are needed for CD5+ DLBCL patients.
Collapse
Affiliation(s)
- K Miyazaki
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu
| | - M Yamaguchi
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu.
| | - R Suzuki
- Department of HSCT Data Management and Biostatistics, Nagoya University Graduate School of Medicine, Nagoya
| | - Y Kobayashi
- Hematology and Stem Cell Transplantation Division
| | - A M Maeshima
- Clinical Laboratory Division, National Cancer Center Hospital, Tokyo
| | - N Niitsu
- Department of Hematology, International Medical Center, Saitama Medical University, Hidaka
| | - D Ennishi
- Department of Medical Oncology, Cancer Institute Hospital, Tokyo
| | - J-I Tamaru
- Department of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe
| | - K Ishizawa
- Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai
| | - M Kashimura
- Department of Hematology, Matsudo City Hospital, Matsudo
| | - Y Kagami
- Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya
| | - K Sunami
- Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama
| | - H Yamane
- Division of Clinical Oncology, Sumitomo-Besshi Hospital Cancer Center, Niihama
| | - M Nishikori
- Department of Hematology and Oncology, Kyoto University, Kyoto
| | - H Kosugi
- Department of Hematology, Ogaki Municipal Hospital, Ogaki
| | - T Yujiri
- Department of Hematology, Yamaguchi University, Yamaguchi
| | - R Hyo
- Department of HSCT Data Management and Biostatistics, Nagoya University Graduate School of Medicine, Nagoya
| | - N Katayama
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu
| | | | - S Nakamura
- Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
6
|
Miyazaki K, Yamaguchi M, Suzuki R, Niitsu N, Ennishi D, Tamaru J, Kagami Y, Katayama N, Kinoshita T, Nakamura S. Retrospective analysis of CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) treated with chemotherapy with or without rituximab. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8551 Background: CD5+ DLBCL comprises 5–10% of DLBCL, and shows a high incidence of central nervous system (CNS) relapse. It has been included in the 4th WHO classification as an immunohistochemical subgroup. To clarify the prognosis and incidence of CNS relapse of CD5+ DLBCL in the rituximab-era, we conducted a multicenter retrospective study. Methods: We analyzed 313 patients (pts) with CD5+ DLBCL who received chemotherapy with (n=164) or without rituximab (n=149). The current series includes 107 out of 120 pts described in our previous study (Haematologica, 2008). Intravascular large B-cell lymphoma, primary CNS DLBCL, and secondary CD5+ DLBCL were excluded from the study population. Results: 313 pts showed the following clinical features: median age, 67 (range: 15–93); M:F=163:150; elevated serum LDH level, 71%; stage III/IV, 64%; IPI HI/H, 53%. No significant difference in clinical background such as the IPI and its five components, B symptom, male sex, and bone marrow involvement was found between pts who were treated with and without rituximab. Pts treated without rituximab received more dose-intensive chemotherapies (CHOP14, third-generation regimen, and high dose cytarabine-based regimen) than those treated with rituximab (24% vs. 7%, P<0.0001). The CR rate was higher in pts received rituximab than those without (81% vs. 65%; P=0.0014). The median follow-up was 28 months in pts who received rituximab (range: 7–77) and 68 months in those who did not (range: 6–187). Overall survival (OS) was significantly superior for pts with rituximab than for those without (2-yr OS: 68% vs. 54%, P=0.003). Multivariate analysis revealed that the use of rituximab was favorably associated with OS (HR=1.81, 95% CI: 1.26–2.58, P=0.001), but dose-intensive chemotherapies did not affect OS. However, the incidence of CNS relapse was not different between the two groups (2-yr CNS relapse rate: 11.9% vs. 11.4%, P=0.91). 16 of the 20 pts (80%) with CNS relapse in the rituximab group had brain parenchymal disease. Conclusions: Our data show that rituximab improves OS of pts with CD5+ DLBCL, but does not prevent CNS relapse. Future prospective studies to decrease CNS disease for CD5+ DLBCL are warranted. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Miyazaki
- CD5+ DLBCL in the R-era Project; Mie University, Tsu, Japan; Nagoya University, Nagoya, Japan; Saitama Medical University, Hidaka, Saitama, Japan; Okayama University, Okayama, Japan; Saitama Medical Center, Saitama Medical University, Kawagoe, Japan; Aichi Cancer Center, Nagoya, Japan
| | - M. Yamaguchi
- CD5+ DLBCL in the R-era Project; Mie University, Tsu, Japan; Nagoya University, Nagoya, Japan; Saitama Medical University, Hidaka, Saitama, Japan; Okayama University, Okayama, Japan; Saitama Medical Center, Saitama Medical University, Kawagoe, Japan; Aichi Cancer Center, Nagoya, Japan
| | - R. Suzuki
- CD5+ DLBCL in the R-era Project; Mie University, Tsu, Japan; Nagoya University, Nagoya, Japan; Saitama Medical University, Hidaka, Saitama, Japan; Okayama University, Okayama, Japan; Saitama Medical Center, Saitama Medical University, Kawagoe, Japan; Aichi Cancer Center, Nagoya, Japan
| | - N. Niitsu
- CD5+ DLBCL in the R-era Project; Mie University, Tsu, Japan; Nagoya University, Nagoya, Japan; Saitama Medical University, Hidaka, Saitama, Japan; Okayama University, Okayama, Japan; Saitama Medical Center, Saitama Medical University, Kawagoe, Japan; Aichi Cancer Center, Nagoya, Japan
| | - D. Ennishi
- CD5+ DLBCL in the R-era Project; Mie University, Tsu, Japan; Nagoya University, Nagoya, Japan; Saitama Medical University, Hidaka, Saitama, Japan; Okayama University, Okayama, Japan; Saitama Medical Center, Saitama Medical University, Kawagoe, Japan; Aichi Cancer Center, Nagoya, Japan
| | - J. Tamaru
- CD5+ DLBCL in the R-era Project; Mie University, Tsu, Japan; Nagoya University, Nagoya, Japan; Saitama Medical University, Hidaka, Saitama, Japan; Okayama University, Okayama, Japan; Saitama Medical Center, Saitama Medical University, Kawagoe, Japan; Aichi Cancer Center, Nagoya, Japan
| | - Y. Kagami
- CD5+ DLBCL in the R-era Project; Mie University, Tsu, Japan; Nagoya University, Nagoya, Japan; Saitama Medical University, Hidaka, Saitama, Japan; Okayama University, Okayama, Japan; Saitama Medical Center, Saitama Medical University, Kawagoe, Japan; Aichi Cancer Center, Nagoya, Japan
| | - N. Katayama
- CD5+ DLBCL in the R-era Project; Mie University, Tsu, Japan; Nagoya University, Nagoya, Japan; Saitama Medical University, Hidaka, Saitama, Japan; Okayama University, Okayama, Japan; Saitama Medical Center, Saitama Medical University, Kawagoe, Japan; Aichi Cancer Center, Nagoya, Japan
| | - T. Kinoshita
- CD5+ DLBCL in the R-era Project; Mie University, Tsu, Japan; Nagoya University, Nagoya, Japan; Saitama Medical University, Hidaka, Saitama, Japan; Okayama University, Okayama, Japan; Saitama Medical Center, Saitama Medical University, Kawagoe, Japan; Aichi Cancer Center, Nagoya, Japan
| | - S. Nakamura
- CD5+ DLBCL in the R-era Project; Mie University, Tsu, Japan; Nagoya University, Nagoya, Japan; Saitama Medical University, Hidaka, Saitama, Japan; Okayama University, Okayama, Japan; Saitama Medical Center, Saitama Medical University, Kawagoe, Japan; Aichi Cancer Center, Nagoya, Japan
| |
Collapse
|
7
|
Ennishi D, Yokoyama M, Terui Y, Asai H, Sakajiri S, Mishima Y, Takahashi S, Komatsu H, Ikeda K, Takeuchi K, Tanimoto M, Hatake K. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol 2008; 20:526-33. [PMID: 19074749 DOI: 10.1093/annonc/mdn677] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Soluble interleukin-2 receptor (SIL-2R) is known to be a prognostic parameter in patients with diffuse large B-cell lymphoma (DLBCL) receiving cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy. However, its prognostic value has not been well known since the introduction of rituximab. PATIENTS AND METHODS We retrospectively evaluated the prognostic impact of SIL-2R in 228 DLBCL patients, comparing 141 rituximab-combined CHOP (RCHOP)-treated patients with 87 CHOP-treated patients as a historical control. RESULTS Patients with high serum SIL-2R showed significantly poorer event-free survival (EFS) and overall survival (OS) than patients with low SIL-2R in both the RCHOP group (2-year EFS, 66% versus 92%, P<0.001; OS, 82% versus 95%, P=0.005) and the CHOP group (2-year EFS, 40% versus 82%; OS, 61% versus 90%, both P<0.001). Multivariate analysis including the five parameters of International Prognostic Index (IPI) and two-categorized IPI revealed that SIL-2R was an independent prognostic factor for EFS and OS in the RCHOP group as well as in the CHOP group. CONCLUSIONS Our results demonstrate that SIL-2R retains its prognostic value in the rituximab era. The prognostic value of SIL-2R in DLBCL patients receiving rituximab-combined chemotherapy should be reassessed on a larger scale and by long-term follow-up.
Collapse
Affiliation(s)
- D Ennishi
- Department of Medical Oncology and Hematology, Cancer Institute Hospital, 3-10-6 Ariake Koto-ku, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, Takahashi S, Komatsu H, Ikeda K, Yamaguchi M, Suzuki R, Tanimoto M, Hatake K. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2008; 19:1921-6. [PMID: 18573805 DOI: 10.1093/annonc/mdn392] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Several biomarkers indicating poor prognosis have been reassessed in patients receiving rituximab combination chemotherapy for diffuse large B-cell lymphoma (DLBCL). However, few studies have investigated outcome in relation to a combination of these biomarkers. In addition, no large-scale studies have reassessed the outcome of patients with CD5-positive DLBCL treated with rituximab. PATIENTS AND METHODS We conducted a retrospective study and investigated the predictive value of three biomarkers -- BCL2, germinal center (GC) phenotype and CD5 -- in 121 DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. RESULTS CD5-positive patients showed significantly poorer event-free survival (EFS) and overall survival (OS) than CD5-negative patients (2-year EFS, 18% versus 73%, P < 0.001; 2-year OS, 45% versus 91%, P = 0.001). However, no significant difference in outcome according to BCL2 or GC phenotype was observed. Multivariate analysis revealed that CD5 expression was a significant prognostic factor for EFS [hazard ratio 14.2, 95% confidence interval (CI) 4.7-43.2] and OS (hazard ratio 20.3, 95% CI 3.6-114.4). CONCLUSIONS CD5 expression was the only significant prognostic factor among the biomarkers examined in this study. Further studies with larger numbers are warranted to confirm the prognostic significance of CD5 expression for patients with DLBCL receiving rituximab-containing chemotherapy.
Collapse
Affiliation(s)
- D Ennishi
- Department of Medical Oncology and Hematology, Cancer Institute Hospital, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|